MIND MEDICINE (MINDMED) INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.26 USD | +1.54% |
|
-7.40% | +153.01% |
| May. 08 | Transcript : Mind Medicine Inc., Q1 2024 Earnings Call, May 08, 2024 | |
| May. 08 | Mind Medicine Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Presenter SpeechCollin Gage (Executives)Good afternoon, and welcome to MindMed's Q2 2021 Earni...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).
Calendar
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
9.26
USD
Average target price
30.86
USD
Spread / Average Target
+233.23%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +153.01% | 666M | |
| +17.96% | 44.96B | |
| +1.17% | 42.65B | |
| +48.77% | 41.85B | |
| -4.27% | 29.04B | |
| +11.42% | 26.08B | |
| -21.39% | 19.03B | |
| +4.86% | 12.75B | |
| +27.29% | 12.06B | |
| -3.50% | 11.75B |
- Stock Market
- Equities
- MNMD Stock
- News Mind Medicine (MindMed) Inc.
- Transcript : Mind Medicine Inc., Q2 2021 Earnings Call, Aug 16, 2021